Health Technology · Pharmaceuticals: Major · NSE: BROOKS · data 2026-10-09

Brooks Laboratories Limited

Health check: Average (5.2/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹70.13

Market cap

₹208 cr

P/E

15.6

P/B

—

ROE

22.3%

ROCE

4.8%

Debt / equity

0.07

Dividend yield

0.00%

1-year return

-45.6%

52-week high

₹130.98

52-week low

₹36.3

Operating margin

5.0%

Growth

Revenue (last 12 months)	₹83 cr
Net profit (last 12 months)	₹13 cr
Sales growth, 3 years (yearly)	10.9%
Profit growth, 3 years (yearly)	—

Similar companies

Nectar Lifesciences Ltd. (NECLIFE) · Accretion Pharmaceuticals Ltd. (ACCPL) · Medico Remedies Ltd. (MEDICO) · Curis Lifesciences Limited (CURIS) · Bal Pharma Limited (BALPHARMA)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open BROOKS in NSE Scanner →